Asarfi Hospital Ltd

Asarfi Hospital Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective July 1, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The date of the board meeting to consider these financial results will be communicated separately.

Asarfi Hospital Ltd's Board of Directors has approved participation in a Public-Private Partnership (PPP) project to operate and augment a 100-bedded District Hospital in Dhanbad, Jharkhand, into a Medical College. The college will have an annual intake capacity of at least 100 MBBS students. The company will furnish a refundable Bid Security of ₹3.52 Crores for this purpose. This approval is solely for the bidding process and does not guarantee project award.

Asarfi Hospital Ltd reports no material deviation in the use of proceeds from its public issue of 5,180,000 equity shares, with a face value of ₹10 each, totaling ₹26.94 Cr. The funds were raised on July 26, 2023, for purposes outlined in the offer document, including capital expenditure for a cancer hospital, land acquisition, and general corporate purposes. A statement of deviation/variation has been enclosed, as per SEBI regulations.

Asarfi Hospital Ltd reported a 42% YoY increase in revenue for FY26, reaching ₹173 Cr. EBITDA margin stood at 20%, and PAT margin at 10%. The growth was driven by improved Average Revenue Per Occupied Bed (ARPOB), better realizations, and an enhanced case mix across both hospital units. IPD revenue grew by 45% YoY, and OPD revenue increased by 14% YoY, supported by growth in patient volumes and higher realizations. ARPOB increased to ₹13,020 (Super-Specialty) and ₹37,128 (Cancer Oncology).

Asarfi Hospital Ltd reported a 42% YoY increase in revenue for FY26, reaching ₹173 Cr. EBITDA margin stood at 20%, and PAT margin at 10%. The growth was driven by improved Average Revenue Per Occupied Bed (ARPOB), better realizations, and an enhanced case mix across both hospital units. IPD revenue grew by 45% YoY, and OPD revenue increased by 14% YoY, supported by growth in patient volumes and higher realizations. ARPOB increased to ₹13,020 (Super-Specialty) and ₹37,128 (Cancer Oncology).

Asarfi Hospital Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, during its meeting held on May 11, 2026. The board meeting, which commenced at 03:00 P.M. and concluded at 5:30 P.M., also included the review of the auditor's report issued by M/s R. K. Thakkar & Co. The auditors issued an unmodified opinion on the standalone and consolidated financial statements.

Asarfi Hospital Ltd reported a 42% YoY increase in revenue for FY26, reaching ₹173 Cr. EBITDA margin stood at 20% and PAT margin at 10%. IPD revenue grew by 46% YoY, and OPD revenue increased by 34% YoY. The growth was driven by specialties including Cardiology, Neurosciences, and Orthopaedics. The Board of Directors approved these results on May 11, 2026.

Asarfi Hospital Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, in a meeting held on May 11, 2026. The board meeting commenced at 3:00 P.M. and concluded at 5:30 P.M. The auditor's report, issued by R. K. Thakkar & Co., Chartered Accountants, contains an unmodified opinion on the financial statements.

Asarfi Hospital Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prohibition of Insider Trading. The trading window will remain closed from April 01, 2026, and will reopen 48 hours after the declaration of the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. The date of the Board Meeting for consideration of the said Audited Financial Results will be intimated in due course.

Asarfi Hospital Ltd, a leading Dhanbad-based healthcare provider, has reported a strong financial performance for the quarter and nine months ended December 31, 2025. The company's revenue for Q3 FY26 rose by 40% YoY to INR 46 Cr, with EBITDA margin at 22% and PAT margin at 12%. The growth was driven by higher patient volumes, improved ARPOB, and improved case mix across both IPD and OPD units. The super-specialty unit and the cancer unit reported strong growth in high-acuity segments, including Cardiology and Neurosciences in the Super-Specialty unit and Head & Neck and Haemato Oncology in the Cancer unit.